Monica Metea 7/25/26 Monica Metea 7/25/26

Measuring the Rewiring: Connectivity Biomarkers for the Next Generation of Psychiatric Drugs

For pharma teams developing neuroplastogens, from psychedelics to next-generation antidepressants, this piece lays out brain functional connectivity, obtained from EEG or fMRI, as the key biomarker for showing that a drug is reorganizing brain circuits. It covers how Lucerum's standardized qEEG methods turn connectivity into a practical, dose-tracked measure usable across every clinical trial phase, with examples from a real MDD program showing the approach in action, from healthy volunteers through patient outcomes.

Monica Metea 7/6/26 Monica Metea 7/6/26

Quantitative EEG in Depression: Predictors of Treatment Response

Quantitative EEG in Depression: Predictors of Treatment Response

Antidepressants and rTMS help roughly half of the patients who try them. Nobody knows which half in advance. That's a solvable problem — and quantitative EEG has quietly spent forty years solving it.

In this piece I give a broad overview of where the field actually is: the early generation of qEEG response predictors that have survived four decades of scrutiny and meta-analysis, the shift now underway toward network- and connectome-based markers that match the modern view of depression as a circuit-level disorder, and the emerging frontier of source-localized, neurotransmitter-informed EEG that could turn precision psychopharmacology from an aspiration into a workflow. I close on where things stand with the FDA and payers, and why the momentum is finally moving in the right direction.

qEEG is not a miracle. But the comparison is not qEEG-versus-perfection — it's versus-the-coin-flip. #qEEG, #Neuroscience, #BrainMapping, #Depression, #Psychiatry, #rTMS, #Antidepressants, #Psychopharmacology, #Connectomics

Monica Metea 7/6/26 Monica Metea 7/6/26

The Third Eye That Went Dark: How an Ancient Light Sensor Became the Body’s Clock, Mood Regulator, and Inner Psychedelic

🧠 The Third Eye That Went Dark

Deep in your brain sits a pea-sized gland that once looked out at the sky. In fish, amphibians, and reptiles, the pineal is literally a light sensor — some lizards still have a rudimentary third eye on top of their skull. In us, it went blind. But it didn't stop reacting to light.

Every night, light hitting your retina takes a long detour from the brain down the spinal cord, and back up — just to tell one small gland: it's dark now. The pineal answers with melatonin, the signal that sets sleep, seasonal reproduction, autonomic tone, and the hand-off from "fight or flight" to "rest and digest."

When this timing loop drifts, mental health follows. In OCD, the clock runs late and quiet — delayed melatonin, smaller pineal glands on MRI. In bipolar disorder, it runs hypersensitive — nighttime light suppresses melatonin twice as much as in healthy controls, even in unaffected relatives.

And here's the twist most people miss: the pineal also produces trace amounts of DMT and pinoline — chemical cousins of the two active ingredients in ayahuasca. Whatever their natural role, their relatives are now delivering rapid antidepressant effects in clinical trials of treatment-resistant depression.

An ancient third eye, blinded but not silenced, still runs a surprising amount of the show.

#Neuroscience #MentalHealth #Chronobiology #Psychedelics #Melatonin